Navigation Links
PrimeraDx Appoints David Jackson as VP of Business Development
Date:1/3/2012

MANSFIELD, Mass., Jan. 3, 2012 /PRNewswire/ -- PrimeraDx today announced that David Jackson has been appointed as the Vice President of Business Development.

"David has extensive capabilities in companion diagnostic partnerships, and his experience with DxS and Qiagen is well aligned with the company's strategy to be the platform of choice in the burgeoning companion diagnostics market," said Matt McManus, President and CEO, PrimeraDx.

"PrimeraDx has the most innovative qPCR based MDx platform in this space," commented Dr. Jackson.  "The strong growth in complex, molecular-based companion diagnostic assays makes this an exciting time to develop strategic alliances based around the high multiplex and multi-modal capabilities of the ICEPlex platform."

David Jackson has over 13 years' experience in the healthcare technology and investment industries.  Most recently David was employed at Qiagen as a member of the Companion Diagnostics Partnerships team in Global Business Development. Prior to Qiagen he held a similar VP role with DxS, which was acquired by Qiagen in 2009.  He has held leadership positions in business and corporate development; strategic marketing; commercialization; and intellectual property analysis. Dr. Jackson earned a doctorate in the medical sciences from the Boston University School of Medicine; is trained and experienced as a US Patent Agent and Securities Analyst.

About PrimeraDx

PrimeraDx is a molecular diagnostics company that has developed, and is commercializing, a novel, game-changing clinical platform which combines PCR with capillary electrophoresis.  The result of combining these two well-known technologies into a bench-top instrument is the ability to deliver highly multiplexed and quantitative, answers to the clinic.  The company is pursuing a two-pronged strategy to sell the system in an Open Platform Mode to clinical labs and to collaborate with pharmaceutical companies to develop high-value companion and enabling diagnostic products.  Users can easily design very complex multi-modal assays that test for disparate target types, like SNPs, expression biomarkers, microRNAs and fusion genes.  PrimeraDx's technology represents the next generation of quantitative PCR.  The Company is backed by a strong group of experienced venture-capital investors, including Abingworth, InterWest Partners, CHL Medical Partners, and Malaysia Technology Development Corporation.  The Company's website is: www.primeradx.com or www.multiplexpcr.com.

CONTACT: Andrew Bond, +1-508-618-2752, abond@primeradx.com


'/>"/>
SOURCE PrimeraDx
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. PrimeraDx Appoints Leroy Hood to its Scientific Advisory Board
2. PrimeraDx Appoints David Heffelfinger as VP of Engineering and Systems Development
3. PrimeraDx Launches the Only System Capable of Simultaneous Quantification of mRNA, microRNA and DNA
4. China Health Resource Appoints USA Acquisition Counsel
5. Winner Medical Appoints BDO China as Independent Auditor
6. Marken Appoints New Head of Global Quality Assurance
7. Delcath Appoints Gregory Gores, M.D. to Medical Advisory Board
8. Qforma Appoints Ian McGuinness as Vice President, Business Development
9. ZONARE Medical Systems Appoints Timothy S. Heher as Vice President of Finance
10. NeoStem Appoints a Biopharmaceutical Business Leader and a Cellular Therapy Expert to its Board of Directors
11. HealthpointCapital Acquires Blue Belt Technologies, Inc. and Appoints Eric B. Timko as President and CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)...  Arkis BioSciences, a leading innovator in the ... cerebrospinal fluid treatments, today announced it has secured ... led by Innova Memphis, followed by Angel Capital ... Arkis, new financing will accelerate the commercialization of ... of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... , June 23, 2016 Any dentist who has ... of the current process. Many of them do not even ... technical difficulties and high laboratory costs involved. And those who ... it at such a high cost that the majority of ... Dr. Parsa Zadeh , founder of Dental Evolutions ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: RO, ... clearance for its Elecsys BRAHMS PCT (procalcitonin) assay as ... or septic shock. With this clearance, Roche is the ... fully integrated solution for sepsis risk assessment and management. ... bacterial infection and PCT levels in blood can aid ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now ... of Final Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. ... Final Cut Pro X users can now reveal the media of their split ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... to revolutionize the emergency ambulance transport experience for the millions of people who ... Uber has disrupted the taxi industry through the use of technology. Now, SmartEMS ...
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, ... the 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, where ... city’s history as home to some of the world’s leading providers of cereal and ...
(Date:6/26/2016)... ... ... Brent Kasmer, a legally blind and certified personal trainer is helping to develop a weight ... app plans to fix the two major problems leading the fitness industry today:, ... program , They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, ... Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. ... skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was ...
Breaking Medicine News(10 mins):